Literature DB >> 8335944

Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis.

A Kojima1, K Iwata, T Seya, M Matsumoto, H Ariga, J P Atkinson, S Nagasawa.   

Abstract

Membrane cofactor protein (MCP) cDNA was transfected into Chinese hamster ovarian tumor (CHO) cells and the functional properties of the expressed protein were studied. Cells adherent to flasks were essential for continuous expression of MCP on CHO cells. If the cells were maintained in noncoated flasks, MCP expression was markedly reduced but upon being transferred to coated flasks reexpressed the protein. MCP expressed on CHO cells had the expected m.w., approximately 50 kDa, and possessed factor I-cofactor activity. By a propidium iodide incorporation assay and by 51Cr release assay, antibody-sensitized CHO cells expressing MCP were protected from C-mediated cytotoxicity. The inhibition of lytic activity correlated with a decrease in C3 deposition. This host cell protective activity was exerted efficiently for the alternative pathway. The classical pathway was not blocked by MCP unless the cells were presensitized with low concentrations of antibody. These results imply that MCP primarily protects host cells from alternative pathway-mediated C3 targeting. In a pathologic state such as autoimmune diseases, the binding of an autoantibody to a target may overcome this protective effect of MCP via the classical pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335944

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

2.  Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells.

Authors:  A Tsujimura; K Shida; M Kitamura; M Nomura; J Takeda; H Tanaka; M Matsumoto; K Matsumiya; A Okuyama; Y Nishimune; M Okabe; T Seya
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

Review 3.  Emission of membrane vesicles: roles in complement resistance, immunity and cancer.

Authors:  David Pilzer; Olivier Gasser; Oren Moskovich; Jurg A Schifferli; Zvi Fishelson
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

4.  Molecular remodelling of human CD46 for xenotransplantation: designing a potent complement regulator without measles virus receptor activity.

Authors:  N A Begum; Y Murakami; S Mikata; M Matsumoto; M Hatanaka; S Nagasawa; T Kinoshita; T Seya
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

5.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

Review 6.  AIM associated with the IgM pentamer: attackers on stand-by at aircraft carrier.

Authors:  Toru Miyazaki; Tomoko Yamazaki; Ryoichi Sugisawa; M Eric Gershwin; Satoko Arai
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

7.  Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.

Authors:  K E Odening; W Li; R Rutz; S Laufs; S Fruehauf; Z Fishelson; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

8.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Authors:  Anna Richards; Elizabeth J Kemp; M Kathryn Liszewski; Judith A Goodship; Anne K Lampe; Ronny Decorte; M Hamza Müslümanoğlu; Salih Kavukcu; Guido Filler; Yves Pirson; Leana S Wen; John P Atkinson; Timothy H J Goodship
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

9.  Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.

Authors:  Srinivas Mamidi; Marc Cinci; Max Hasmann; Volker Fehring; Michael Kirschfink
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

Review 10.  Inhibiting complement activation on cells at the step of C3 cleavage.

Authors:  M Kathryn Liszewski; Celia J Fang; John P Atkinson
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.